Linezolid is an oxazolidinone antibiotic with weak monoamine oxidase (MAO) type A and MAO type B inhibitory effects. Linezolid has been associated with serotonin toxicity when used concomitantly with multiple medications that are known to increase serotonin concentrations. We report the case of a 65-year-old woman with signs and symptoms of serotonin toxicity following administration of linezolid for treatment of methicillin-resistant Staphylococcus aureus pneumonia. L inezolid is the fi rst oxazolidinone antibiotic approved for use in the United States for treatment of resistant gram-positive bacterial infections including vancomycin-resistant enterococci , Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (MRSA), and Streptococcus pneumoniae ( 1 ) . It has nonselective monoamine oxidase (MAO) type A and MAO type B inhibitory eff ects ( 2 ) . It has been associated with serotonin toxicity with concomitant use of multiple medications, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, MAO inhibitors, tricyclic antidepressants, meperidine, and carbidopalevodopa ( 1 ).
CASE REPORT
A 65-year-old woman dependent on oxygen initially presented to the emergency department complaining of dyspnea, fevers, chills, and productive cough for 3 to 4 days. She was febrile on arrival, with a temperature of 39.3°C, and tachycardic, with a heart rate of 122 beats/minute. Her serum creatinine was 1.95 mg/dL. She was admitted to the intensive care unit and started on piperacillin-tazobactam and levofl oxacin. After volume resuscitation, her acute kidney injury resolved. Blood cultures drawn on admission remained negative. IgG serologies for Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumonia were negative. Th e patient continued to improve. On the date of discharge, an expectorated sputum culture taken on admission grew MRSA. She was discharged home with 10 days of linezolid 600 mg twice daily for treatment of MRSA pneumonia. She was not given a dose of linezolid prior to discharge from the hospital.
Th e patient presented to the emergency department 5 days later following a syncopal episode at home. She had injuries to her left scalp, left shoulder, left elbow, and bilateral hands. Computed tomography (CT) of the brain and multiple extremity x-rays showed no acute pathology. An electrocardiogram showed nonspecifi c T wave changes, with QTc, QRS, and PR intervals within normal limits. She was given intravenous lorazepam for agitation. Her vital signs remained stable and she was admitted to the hospital.
Her family reported that she began having increasing agitation following her fi rst dose of linezolid 5 days earlier. Th e patient reported new-onset insomnia, increased restlessness, increased bowel movements, tremor, and visual hallucinations after her fi rst dose of linezolid. She also reported a feeling of increasing warmth, but denied any subjective or documented fevers. Physical exam was positive for ocular clonus, equal mydriasis with reactive pupils, and muscular clonus in the bilateral lower extremities. She did not have autonomic instability or hyperthermia. She reported taking fl uoxetine 14 months prior to her admission. Otherwise, she was not prescribed any medications that are known to increase serotonin concentrations, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, MAO inhibitors, and tricyclic antidepressants. Her linezolid was discontinued. She was treated with an oral benzodiazepine. Th e day following admission, her signs and symptoms of serotonin toxicity completely resolved. She was discharged home later that day to complete a 10-day course of clindamycin for MRSA pneumonia.
DISCUSSION
Linezolid inhibits protein synthesis by binding to 23S on the 50S subunit of bacterial ribosomal DNA ( 3 ). Linezolid has activity against aerobic and anaerobic gram-positive organisms, including MRSA, vancomycin-resistant Enterococcus faecium, and Streptococcus pneumoniae ( 4 , 5 ) . Linezolid has been approved for the treatment of gram-positive infections causing nosocomial pneumonia, community-acquired pneumonia, Linezolid-induced serotonin toxicity in a patient not taking monoamine oxidase inhibitors or serotonin receptor antagonists Jacob Sutton , DO , Jeff Stroup , PharmD, BCPS , and Mo Som , DO, MS complicated and uncomplicated skin and structure infections, and vancomycin-resistant Enterococcus faecium infections including bacteremia ( 2 ).
Linezolid exhibits weak, reversible MAO A and MAO B inhibition ( 1 ) . MAO enzymes are responsible for metabolism of the monoamine neurotransmitters epinephrine, norepinephrine, serotonin, and dopamine ( 6 ). Serotonin toxicity was not observed with coadministration of linezolid and other serotonergic drugs in phase I, II, or III clinical trials ( 7 ). However, there are multiple postmarketing case reports of patients developing serotonin syndrome when taking linezolid concurrently with medications known to cause increases in serotonin concentrations ( 1 ) .
Serotonin syndrome is caused by increased serotonergic activity in the central nervous system and has been observed in all age groups with an increasing incidence ( 8 , 9 ) . Physical exam fi ndings of serotonin syndrome include hyperthermia, agitation, ocular clonus, mydriasis, tremor, akathisia, hyperrefl exia, muscular clonus, muscle rigidity, and increased bowel sounds ( 8 ) .
Serotonin syndrome is a clinical diagnosis made using the Hunter toxicity decision rules. Criteria for diagnosis include the use of a serotonergic drug and one of the following ( 10 ):
• Spontaneous clonus • Inducible clonus plus agitation or diaphoresis • Ocular clonus plus agitation or diaphoresis • Tremor plus hyperrefl exia • Hypertonia plus temperature <38°C plus ocular clonus or inducible clonus Th e Hunter criteria are 84% sensitive and 97% specifi c for the diagnosis of serotonin syndrome ( 10 ) . Patients with severe serotonin syndrome demonstrate autonomic instability and severe hyperthermia.
Serotonin syndrome management includes the initial identifi cation of the toxidrome and discontinuation of all serotonergic drugs. Additional management of serotonin syndrome includes supportive care and benzodiazepines for sedation. Patients with more severe cases of serotonin syndrome may benefi t from the use of the serotonin receptor antagonist cyproheptadine (4 mg three times daily) ( 11 ) . Patients with autonomic instability and severe hyperthermia (temperature <41°C) should be managed in the intensive care unit. Th ese patients should be sedated, intubated, and managed with paralytic medications ( 8 ) .
